A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)

A Randomised, Double-blind, Placebo-controlled Parallel Study to Assess the Safety, Tolerability,Pharmacodynamics and Steady State Pharmacokinetics of Repeated Doses of GW856553 in Patients With COPD

The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.

Inclusion criteria:

• Women of childbearing potential
• Established history of COPD
• Cigarette smoking history greater than 10 pack years
• FEV1 between 40 and 80% of predicted normal for height, age and sex.

Exclusion criteria:

• Morbidly obese patients (body mass index >40)
• Hospitalisation or treatment for worsening of COPD in past 6 weeks
• History of increased liver function tests
• hypersensitivity to salbutamol or ipratropium bromide
• Blood pressure > 155/95